arrow
M

Mary Wu

the francis crick institute
H指数:36
被引数:6,228

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mucosal IgA to pre-fusion F protein predicts protection from RSV infection in a high burden setting

黏膜IgA对前融合F蛋白的反应预测高负担地区呼吸道合胞病毒感染的防护效果

2026-08-260
OA
Improved Resolution of Influenza Vaccination Responses With High-Throughput Live Virus Microneutralisation

通过高通量活病毒微量中和技术提高流感疫苗接种反应的分辨率

2025-08-140
PREAI
Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign
LANCET
IF88.5
2024-03-011
OAAI
SARS-CoV-2 mucosal neutralising immunity after vaccination
2024-01-013
OAAI
CD4+and CD8+T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study

CD4和CD8 T细胞和抗体与预防Delta疫苗突破性感染相关: PITCH研究中的巢式病例对照研究

MBIO
IF4.7
2023-10-314
OAAI
Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest London

独立的SARS-CoV-2人员测试保护了伦敦西北部的学术和医疗机构

LANCET
IF88.5
2023-07-014
OAAI
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
2023-07-0113
OAAI
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
2023-06-2016
OAAI
Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes
2023-01-209
OAAI
WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed
LANCET
IF88.5
2022-12-0125
OAAI
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study

疫苗接种前预防SARS-CoV-2再感染的抗体相关性: SIREN研究中的嵌套病例对照

2022-11-0123
OAAI
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

血癌患者在第四次新型冠状病毒肺炎疫苗剂量或感染后针对SARS-CoV-2变异的功能性免疫反应

2022-10-0116
OAAI
Three-dose vaccination elicits neutralising antibodies against omicron
LANCET
IF88.5
2022-02-0170
OAAI